From binding to in vivo efficacy: biochemical, biophysical, cellular, mechanistic, and translational evaluation of STAT6 degraders, ready to deploy for your program

STAT6 is one of the most actively pursued degradation targets in immunology today, and validating a STAT6 degrader end to end takes a platform purpose-built for the job. PreceDo's STAT6 Toolbox delivers exactly that: a single, integrated workflow spanning biophysics, cellular pharmacology, primary and patient-derived cells, selectivity, PK/PD, and disease models.

The STAT6 pathway is activated when IL4 or IL13 binds their receptors, triggering JAK1/JAK3 phosphorylation and recruitment of STAT6. Phosphorylated STAT6 dimerizes and translocates to the nucleus, where it drives transcriptional programs central to type 2 immunity:

• GATA3-dependent Th2 differentiation
• IgE class switching in B cells
• M2 macrophage polarization
• Type 2 inflammatory cytokine production

Under homeostasis, STAT6 is tightly regulated by phosphatases, SOCS proteins, and ubiquitin-mediated degradation. Dysregulation leads to chronic type 2 inflammation, contributing to atopic dermatitis, asthma, eosinophilic disorders, fibrosis, and tumor immune evasion. This makes STAT6 a compelling therapeutic target across immunology and oncology.

Upstream blockade (e.g., Dupilumab) validated the clinical relevance of IL‑4/IL‑13–STAT6 signaling. Direct STAT6-targeting modalities were rapidly advancing, including small molecules, RNA therapeutics, and targeted protein degradation (TPD). STAT6 degraders eliminated the protein rather than transiently inhibiting it, enabling deeper and more durable pathway suppression. Programs such as Kymera KT‑621 and Simcere SIM0712 highlighted the field’s momentum. As the field accelerated, degrader programs needed a validation partner who could move at the same pace, which was exactly the gap PreceDo's STAT6 Toolbox was built to fill.

PreceDo’s STAT6 Biological Evaluation Criteria were built on a fully integrated discovery platform. We applied a reference degrader, which demonstrated outstanding in vitro and in vivo performance, and applied it across a comprehensive suite of biophysical, cellular, pathway, selectivity, and in vivo assays to establish rigorous validation standards for STAT6 degraders.

Compound	ka(1/Ms)	kd(1/s)	KD
AK-1690	6.052E+5	0.030290	50.1 nM
I-796	1.698E+5	0.007098	41.8 nM

SPR analysis demonstrated that both AK-1690 and I-796 bound STAT6 with nanomolar affinity. The association/dissociation kinetics indicated stable interaction with STAT6.

I-796 induced rapid and near-complete degradation of STAT6 in engineered A549-STAT6-HiBiT cells. The steep degradation curve and high maximal degradation indicated efficient recruitment of STAT6 to CRBN and robust proteasomal processing. This assay also demonstrated suitability for high-throughput screening.

In hematopoietic cell lines, I-796 maintained strong degradation activity. The Western blot patterns revealed clear dose-dependent loss of STAT6 protein.

DC50	CD3+ T cells	CD19+ B cells	PBMCs
AK-1690 (nM)	35.91	56.30	36.33
I-796 (pM)	46	103	44

DC50	CD3+ T cells	CD19+ B cells	PBMCs
I-796 (nM)	0.198	0.455	0.233

I-796 retained strong activity in AD patient-derived immune cells, demonstrating its ability to overcome disease-associated inflammatory signaling. The suppression of CCL17, a key Th2 chemokine, indicated functional pathway inhibition beyond protein degradation.

DC50	CD3+ T cells	CD19+ B cells	PBMCs
I-796 (nM)	0.171	0.315	0.188

Similar to AD samples, CU patient cells showed robust STAT6 degradation and cytokine suppression. This suggested that I-796 could modulate STAT6-driven inflammation across multiple type 2 inflammatory diseases.

I-796 effectively blocked IL4/IL13 induced STAT6 phosphorylation, demonstrating that degradation translated into functional pathway suppression. AK-1690 showed weaker inhibition, consistent with its lower degradation potency.

STAT assays	I-796, IC50 (nM)
STAT1	>1000
STAT2	>1000
STAT3	>1000
STAT4	>1000
STAT5	>1000
STAT6	0.046

STAT assays	I-796, IC50 (nM)
IFN-α induced pSTAT1	>1000
IFN-α induced pSTAT2 in CD3+ cells	>1000
IFN-α induced pSTAT2 in CD19+ cells	>1000
IL-10 induced pSTAT3	>1000
IL-12 induced pSTAT4	>1000
IL-2 induced pSTAT5	>1000
IL-4 induced pSTAT6	0.656
IL-13 induced pSTAT6	1.874

STAT assays	I-796, IC50 (nM)
Hela-GAS-luc (STAT1)	>1000
Hut78-GAS-luc (STAT1)	>1000
HEK293-ISRE-luc (STAT1/2)	>1000
Hut78-ISRE-luc (STAT1/2)	>1000
Ba/F3-STAT5-luc (STAT5)	>1000
Ba/F3-STAT6-luc (STAT6)	1.3

Route of Administration	Dosage (mg/kg)	T1/2 (h)	Tmax (h)	Cmax (ng/mL)	AUC(0-t) (h·ng/mL)	AUC(0-∞) (h·ng/mL)	Vss (L/kg)	CL (mL/min/kg)	F (%)
IV	1	11.3	0.083	6397	71350	93113	0.171	0.180	—
PO	10	10.5	2.33	5620	85659	108539	—	—	11.66

I-796 displayed favorable PK properties, including sustained exposure and measurable oral bioavailability. The long half-life supported once-daily dosing in vivo.

I-796 induced clear STAT6 degradation in spleen and blood 24 hours post-dose, demonstrating that the degrader mechanism was preserved in vivo.

I-796 significantly reduced MC903-induced IgE elevation, whereas it showed no appreciable effect on ear thickness in this model.

Both I-796 and dupilumab mildly ameliorated MC903-induced ear thickness increase and partially reversed MC903-induced body weight loss.

Both I-796 and dupilumab significantly reduced MC903-elevated IgE levels.

In the vehicle group, marked hyperkeratosis, parakeratosis, significant epidermal thickening, and pronounced dermal inflammatory cell infiltration were observed.

Neither I-796 nor dupilumab showed obvious improvement in the pathological damage to the stratum corneum, epidermis, or dermis in ear skin from the AD model.

I-796 significantly reduced IgE, airway inflammation, mucus production, and multiple Th2 cytokines. These results demonstrated strong functional suppression of STAT6-driven allergic inflammation.

[1] Recludix Pharma. (2025). Corporate Presentation (p. 10/11). Retrieved from https://recludixpharma.com/wp-content/uploads/2025/01/Recludix-Presentation_January-2025.pdf